Gastroenterology Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (Gastrointestinal Tract Diseases, Gastrointestinal Organs Diseases), By Applications (Hospitals, Clinics, Drug Store/Pharmacies, Others), Regional Insights and Forecast to 2035
- Last Updated: 04-November-2026
- Base Year: 2025
- Historical Data: 2021 - 2024
- Region: Global
- Format: PDF
- Report ID: GGI100844
- SKU ID: 30425264
- Pages: 106
Download FREE Sample
Gastroenterology Market Size
The Global Gastroenterology Market size was USD 62955.3 Million in 2025 and is projected to touch USD 67475.41 Million in 2026 and USD 72320.2 Million in 2027 to USD 125932.16 Million by 2035, exhibiting a CAGR of 7.18% during the forecast period [2026-2035].
Growth in the Gastroenterology Market is being shaped by a steady shift from reactive treatment toward early detection and long-term disease management. Diagnostic and screening procedures account for close to 55% of overall activity, while therapeutic interventions contribute about 45%. Rising awareness of digestive health, wider endoscopy access and a larger pool of patients living with chronic conditions keep demand steady across care settings, and procedure-linked products continue to hold the larger share of purchasing decisions.
![]()
In the US Gastroenterology Market, adoption of colorectal screening and advanced endoscopic platforms keeps the country at roughly 36% of global activity. Around 70% of eligible adults now participate in some form of screening, and nearly 60% of procedures are performed in outpatient and ambulatory settings, which supports steady demand for devices and therapies.
Key Findings
- Market Size: Starting at $67475.41M in 2026, projected to touch $72320.2M in 2027 to $125932.16M by 2035 at a CAGR of 7.18%.
- Growth Drivers: Screening participation near 70% and a 12% rise in endoscopy volumes lift demand, while 9% annual growth in biologic use supports therapy uptake.
- Trends: Single-use scopes now reach 18% of procedures, AI-assisted detection improves polyp identification by 14%, and home-based testing grows 11% among adults.
- Key Players: Boston Scientific, Olympus Corp. of the Americas, Takeda Pharmaceuticals USA, Johnson and Johnson, Fujifilm Medical Systems USA & more.
- Regional Insights: North America leads with 38%, Europe holds 27%, Asia-Pacific captures 25% and Middle East & Africa accounts for 10%, with Asia-Pacific gaining fastest.
- Challenges: Equipment and reprocessing costs absorb up to 22% of departmental budgets, while specialist shortages leave nearly 15% of procedure slots unfilled in several regions.
- Industry Impact: Ambulatory centers now handle 60% of procedures, and digital workflow tools cut reporting time by 20%, reshaping purchasing priorities across providers.
- Recent Developments: Next-generation screening tests reach 94% cancer sensitivity, and new biologic indications widen the treatable population by about 10%.
The Gastroenterology Market is increasingly defined by prevention. Nearly 40% of colorectal cancers are considered preventable through timely screening, which pushes health systems to invest in capacity, while about 28% of procedure growth now comes from patients below the traditional screening age band.
Product mix is also changing. Therapy-led spending contributes close to 45% of demand as chronic inflammatory conditions are managed over longer periods, and procedure-linked consumables make up roughly 30% of recurring purchases, giving suppliers a more predictable demand base than capital equipment alone.
![]()
Gastroenterology Market Trends
Technology adoption is the clearest force reshaping the Gastroenterology Market. Artificial intelligence modules that flag suspicious tissue in real time are now used in nearly 30% of high-volume endoscopy units, and early evaluations suggest they raise adenoma detection by about 14%. Providers are pairing these tools with cloud-based reporting, which trims documentation time by close to 20% and lets specialists spend more of each session on patients.
Infection control and convenience are moving purchasing patterns as well. Single-use endoscopes now represent around 18% of procedures where cross-contamination risk is a concern, and non-invasive stool and blood-based tests are drawing about 11% more first-time screeners than conventional pathways. Meanwhile, biologic and targeted therapies are taking a growing share of inflammatory bowel disease treatment, and patient-support programs are improving adherence by roughly 12%, which strengthens long-term therapy demand.
Gastroenterology Market Dynamics
Growth in minimally invasive and AI-guided procedures
Minimally invasive care represents the strongest opening for suppliers in the Gastroenterology Market. Endoscopic techniques now replace open surgery in nearly 65% of eligible digestive interventions, shortening hospital stays by about 30% and lowering complication rates. Emerging economies add further room, as screening coverage in several of them remains below 30% of the eligible population, leaving a large untapped patient base. Vendors that combine compact imaging systems, decision-support software and affordable consumables can serve smaller clinics and ambulatory centers that currently account for less than 25% of advanced device installations in these regions. Partnerships with local distributors and training programs can speed adoption further.
Rising burden of digestive and colorectal disorders
The growing burden of digestive disease keeps procedure and therapy demand on an upward path. Chronic conditions such as reflux disease, inflammatory bowel disease and liver-related disorders affect an estimated 20% of adults worldwide, and incidence of early-onset colorectal cancer has risen by nearly 2% each year in several markets. Ageing populations add pressure, since adults above 50 account for about 65% of screening and diagnostic volumes. Public screening programs, employer wellness initiatives and better insurance coverage have lifted participation by roughly 10%, converting more undiagnosed cases into treated ones and giving manufacturers and pharmaceutical firms a broader, more reliable patient pipeline across both developed and developing health systems.
| Market Driver | Impact Rank | Contribution | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Rising prevalence of digestive and gastrointestinal disorders | High | 2.9% | High | High | Medium |
| Expanding colorectal cancer screening participation | High | 2.4% | High | Medium | Medium |
| Growth in endoscopy and therapeutic procedure volumes | Medium | 1.9% | Medium | High | Medium |
| AI-assisted diagnostics and single-use endoscope adoption | Medium | 1.5% | Medium | High | High |
| Ageing population and improved treatment access | Low | 1.1% | Medium | Medium | Low |
| Others | Lowest | 0.8% | Low | Low | Low |
| Total Driver Contribution | 10.60% |
RESTRAINTS
"High equipment costs and reimbursement pressure"
Cost pressure is the main brake on faster expansion of the Gastroenterology Market. Advanced endoscopy towers, imaging upgrades and reprocessing infrastructure can absorb up to 22% of a department's capital budget, which delays replacement cycles in smaller hospitals and clinics. Reimbursement rates for routine procedures have tightened by roughly 5% in several markets, squeezing provider margins and slowing investment in new platforms. Stringent device approval pathways add further delay, as nearly 20% of new product submissions require additional clinical evidence. Together, these factors temper adoption in price-sensitive regions and push buyers toward longer evaluation periods before committing to new technology.
| Market Restraint | Impact Rank | Negative CAGR Impact | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| High cost of advanced endoscopic equipment and reprocessing | High | -1.5% | High | Medium | Medium |
| Shortage of trained gastroenterologists and procedural capacity | Medium | -1.0% | Medium | Medium | Low |
| Stringent regulatory approvals and reimbursement pressure | Low | -0.6% | Medium | Low | Low |
| Others | Lowest | -0.32% | Low | Low | Low |
| Total Restraint Impact | -3.42% |
CHALLENGES
"Workforce gaps and infection-control burden"
Operational complexity remains a persistent challenge for providers and suppliers. A shortage of trained endoscopists leaves nearly 15% of procedure slots unfilled in several regions, extending waiting times for screening and diagnosis. Duodenoscope reprocessing demands strict protocols, and lapses have prompted about 10% of facilities to revise their cleaning workflows or move toward disposable alternatives, which raises per-procedure costs. Data integration is another hurdle, since close to 35% of smaller clinics still run fragmented records, limiting the benefit of AI and analytics tools. Patient reluctance also matters, as roughly 25% of eligible adults delay screening because of discomfort or cost concerns, restraining volume growth.
Segmentation Analysis
The Gastroenterology Market is segmented by disease type and by care setting, and each lens shows a different growth pattern. Disease segmentation separates conditions of the digestive tract from those of associated organs, while application segmentation tracks where diagnosis and treatment are delivered. Hospitals remain the anchor of spending, but outpatient settings are gaining about 3% of share each year as procedures migrate to lower-cost venues, and pharmacies are becoming an important access point for long-term medication.
By Type
Gastrointestinal Tract Diseases
Gastrointestinal tract diseases lead the market with roughly 58% share, driven by reflux disease, irritable bowel syndrome, inflammatory bowel disease, ulcers and colorectal conditions. Screening colonoscopy alone contributes close to 30% of procedures within this segment, while chronic inflammatory conditions sustain recurring therapy demand. Rising dietary and lifestyle risk factors have lifted diagnosed cases by about 6% in several developed markets, keeping both endoscopic and pharmaceutical products firmly in demand.
Gastrointestinal Organs Diseases
Gastrointestinal organ diseases account for about 42% of the market and cover conditions of the liver, pancreas, gallbladder and related structures. Fatty liver disease is a notable growth engine, affecting nearly 25% of adults in many regions and expanding demand for imaging, elastography and therapeutic endoscopy. Pancreatic and biliary interventions are growing faster than average, supported by a 9% annual rise in advanced endoscopic ultrasound use, though treatment complexity keeps procedures concentrated in specialist centers.
By Application
Hospitals
Hospitals hold the largest application share at about 49%, reflecting their role in complex diagnostics, surgery and inpatient care. Around 70% of therapeutic endoscopy and advanced imaging procedures are still performed in hospital settings, supported by multidisciplinary teams and capital budgets. However, pressure to reduce costs is moving roughly 3% of routine procedures to outpatient venues annually, pushing hospitals to concentrate on higher-acuity cases.
Clinics
Clinics represent nearly 24% of the Gastroenterology Market and are the fastest-expanding care setting. Ambulatory and specialty clinics now perform close to 40% of routine screening colonoscopies, benefiting from shorter wait times and lower procedure charges. Investment in compact endoscopy systems and disposable accessories has raised clinic procedure capacity by about 12%, making this setting central to screening expansion and follow-up care.
Drug Store/Pharmacies
Drug stores and pharmacies capture about 19% of application share, anchored by prescription therapies and over-the-counter digestive remedies. Acid suppressants, laxatives and anti-inflammatory medicines make up nearly 65% of segment turnover, while specialty pharmacy channels are growing at roughly 8% annually as biologics require managed distribution. Digital prescription refills and pharmacist counselling are improving adherence by around 10%.
Others
The others category contributes approximately 8% and includes ambulatory surgical centers, diagnostic laboratories, academic institutions and home-care providers. Stand-alone laboratories process a growing volume of stool-based and molecular screening tests, with demand rising about 11% as non-invasive options gain trust. Home-based monitoring and telehealth follow-ups are also widening reach in remote communities, though they still represent a modest portion of overall activity.
![]()
Gastroenterology Market Regional Outlook
Regional performance in the Gastroenterology Market reflects differences in screening maturity, reimbursement and healthcare capacity. North America leads with a 38% share, Europe follows with 27%, Asia-Pacific holds 25% and Middle East & Africa contributes 10%, together covering the full 100% of global activity. Asia-Pacific is gaining ground fastest as screening programs scale, while mature regions focus on technology upgrades and outpatient migration.
North America
North America commands about 38% of the Gastroenterology Market, supported by structured screening programs, strong insurance coverage and early adoption of advanced endoscopy. Nearly 70% of eligible adults take part in colorectal screening, and about 60% of procedures occur outside hospital walls. AI-assisted detection is already present in close to 30% of high-volume units, and demand for biologic therapies continues to rise as inflammatory bowel disease prevalence increases.
Europe
Europe accounts for roughly 27% of the market, shaped by organized national screening programs and publicly funded care. Screening participation averages near 55% across the region, with higher uptake in Northern and Western countries. Sustainability goals are boosting interest in reusable and low-waste endoscopy solutions, and about 20% of hospitals have started pilot programs for digital reporting. Biosimilar adoption lowers therapy costs by close to 15%, widening patient access.
Asia-Pacific
Asia-Pacific holds about 25% of the Gastroenterology Market and is the quickest-growing region. Rising incomes, urbanization and dietary change have lifted digestive disorder diagnoses by nearly 8% in several economies, while screening coverage still sits below 35% in many areas, leaving large headroom. Government-backed hospital expansion and local manufacturing are improving device access, and private clinic networks now handle about 30% of endoscopy volumes in major cities.
Middle East & Africa
Middle East & Africa represents about 10% of the market, with growth concentrated in Gulf economies investing in specialist hospitals and medical tourism. Screening participation remains below 25% in much of the region, and nearly 40% of advanced procedures are performed in a small number of tertiary centers. Public-private partnerships and training initiatives are expanding capacity, and imported endoscopy systems account for over 70% of installed equipment.
List of Key Gastroenterology Market Companies Profiled
- Modernizing Medicine Co.
- Evoke Pharma
- Cogentix Medical
- Physicians Endoscopy
- Synergy Pharmaceuticals
- Interscope
- US Endoscopy Group
- Takeda Pharmaceuticals USA
- Allergan Pharmaceuticals
- Exact Sciences Corp. (colorectal cancer)
- Boston Scientific
- Shaili Endoscopy
- Pentax Medical USA
- Fujifilm Medical Systems USA
- Motus GI
- Olympus Corp. of the Americas
- Salix Pharmaceuticals
- EndoGastric Solutions
- EndoChoice
- Johnson and Johnson
Top Companies with Highest Market Share
- Olympus Corp. of the Americas: Holds roughly 12% of the market, led by flexible endoscopy systems with over 60% share in installed scopes in many hospitals.
- Boston Scientific: Commands close to 9% share, supported by a 25% contribution from single-use and therapeutic endoscopy accessories.
Investment Analysis and Opportunities
Investment in the Gastroenterology Market is flowing toward screening technology, minimally invasive devices and targeted therapies. Roughly 35% of recent capital activity is directed at AI-enabled diagnostics and imaging, while about 25% supports single-use and low-infection-risk endoscopy platforms. Therapeutics attract close to 30% of funding, particularly biologics and microbiome-based approaches. Ambulatory surgical centers are an attractive entry point, since they are expanding procedure capacity by nearly 12% and favor compact, cost-efficient equipment. Emerging regions offer additional upside, as screening coverage below 35% implies a large unserved population. Partnerships between device makers, software developers and healthcare providers are lowering adoption risk, and bundled service models are improving equipment utilization rates by about 15%.
New Products Development
Product innovation in the Gastroenterology Market is concentrated on visualization, disposability and non-invasive detection. New high-definition endoscopes with built-in artificial intelligence are improving lesion detection by about 14%, and compact single-use scopes are lowering reprocessing workload by nearly 40% in facilities that adopt them. Capsule-based and blood-based screening tools are broadening participation, with early users reporting an 11% rise in first-time screeners. In pharmaceuticals, selective biologics and oral small-molecule therapies are improving remission outcomes for a significant share of patients with inflammatory bowel disease, and subcutaneous formulations are increasing convenience, lifting adherence by roughly 10%. Digital companion apps for symptom tracking further strengthen patient engagement.
Recent Developments
- April 2024– Takeda Pharmaceuticals USA expands subcutaneous Crohn's disease option: Takeda secured approval for a pen-based maintenance option in Crohn's disease, giving patients a self-administered alternative to infusion visits. Convenient formats can raise adherence by about 10% and shift nearly 20% of maintenance dosing away from infusion centers, reinforcing the role of home-based biologic care.
- September 2024– Johnson and Johnson wins approval for ulcerative colitis use: Johnson and Johnson received clearance for an interleukin-23 inhibitor in adults with moderately to severely active ulcerative colitis, widening choices in a segment where around 30% of patients do not respond adequately to earlier biologics, and strengthening its position in inflammatory bowel disease.
- October 2024– Exact Sciences Corp. gains approval for next-generation stool test: Exact Sciences obtained approval for an upgraded multi-target stool DNA test with about 94% sensitivity for colorectal cancer. The improvement also lowers false positives, which supports follow-up efficiency and encourages screening among the roughly 30% of eligible adults still unscreened.
- March 2025– Exact Sciences Corp. launches upgraded colorectal screening test commercially: The company began commercial rollout of its enhanced stool-based test, aiming to raise participation among adults aged 45 and above. Non-invasive tests are drawing close to 11% more first-time screeners, and wider availability increases the volume of downstream colonoscopies.
- March 2025– Johnson and Johnson extends inflammatory bowel therapy to Crohn's disease: Johnson and Johnson added a Crohn's disease indication for its interleukin-23 therapy, broadening the treatable population by roughly 10% across its inflammatory bowel portfolio. The move intensifies competition among biologic makers and supports growing therapy-led spending, now near 45% of demand.
Report Coverage
This report on the Gastroenterology Market evaluates the competitive landscape, segmentation structure and regional performance using a balanced mix of qualitative assessment and percentage-based indicators. Coverage includes disease segmentation, where tract-related conditions hold about 58% and organ-related conditions about 42%, and application analysis spanning hospitals at 49%, clinics at 24%, drug stores and pharmacies at 19% and other settings at 8%. Regional analysis covers North America at 38%, Europe at 27%, Asia-Pacific at 25% and Middle East & Africa at 10%. The study profiles twenty leading companies, reviews drivers, restraints, opportunities and challenges, and assesses technology shifts such as AI-assisted detection and single-use endoscopy. Investment themes, new product activity and recent manufacturer developments are included to support strategic planning, partnership screening and product positioning decisions.
Gastroenterology Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 67475.41 Million in 2026 |
|
|
Market Size Value By |
USD 125932.16 Million by 2035 |
|
|
Growth Rate |
CAGR of 7.18% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Download FREE Sample
Frequently Asked Questions
-
What value is the Gastroenterology Market expected to touch by 2035?
The global Gastroenterology Market is expected to reach USD 125932.16 Million by 2035.
-
What CAGR is the Gastroenterology Market expected to exhibit by 2035?
The Gastroenterology Market is expected to exhibit a CAGR of 7.18% by 2035.
-
Who are the top players in the Gastroenterology Market?
Modernizing Medicine Co., Evoke Pharma, Cogentix Medical, Physicians Endoscopy, Synergy Pharmaceuticals, Interscope, US Endoscopy Group, Takeda Pharmaceuticals USA, Allergan Pharmaceuticals, Exact Sciences Corp. (colorectal cancer), Boston Scientific, Shaili Endoscopy, Pentax Medical USA, Fujifilm Medical Systems USA, Motus GI, Olympus Corp. of the Americas, Salix Pharmaceuticals, EndoGastric Solutions, EndoChoice, Johnson and Johnson
-
What was the value of the Gastroenterology Market in 2025?
In 2025, the Gastroenterology Market value stood at USD 62955.3 Million.
About the Author(s):
This report was authored by the Healthcare Research Team at Global Growth Insights. The team specializes in pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, healthcare services, and life sciences. Their expertise includes market sizing, regulatory analysis, competitive benchmarking, and healthcare trend forecasting to support strategic investment and business growth.
Our Clients
Download FREE Sample